English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Benzyl-14C-1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl) piperazine dihydrochloride (14C-KB-2796), a new cerebral vasodilator, was synthesized in order to investigate the metabolic fate. The synthesis of carboxy-14C-2,3,4-trimethoxybenzoic acid (IV) was accomplished by the reaction of 2,3,4-trimethoxybromobenzene (II) with ter-butyllithium followed by carboxylation with 14C-carbon dioxide generated from 14C-barium carbonate. Formyl-14C-2,3,4-trimethoxybenzaldehyde (VI) was prepared by the reduction of the methyl ester of IV. The free base of 14C-KB-2796 was obtained by the condensation of VI with bis(4-fluorophenyl)methyl-piperazine, and converted to I. An overall radiochemical yield from 14C-barium carbonate was 39%, the specific activity was 1,816.7 MBq/mmol (49.1 mCi/mmol) and its radiochemical purity was 99% in reverse isotope dilution analysis and thin layer chromatographic method.

Synthesis of carbon-14 labeled 1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (14C-KB-2796).